A silent epidemic is moving across the country. Each year, from one in five children in the U.S., show signs or symptoms of a mental health disorder, be it depression, anxiety or substance abuse.
Two psychedelics companies have announced they’ll be collaborating to offer ketamine infusions in the US and psilocybin clinical retreats internationally with a special focus on access needs for veterans.
Awakn Life Sciences Corp. (OTCQB: AWKNF), the biotech company focused on addiction treatments, has signed a licensing partnership agreement with US ketamine therapy clinics owner Revitalist Lifestyle and Wellness Ltd.
By Javier Hasse and Aaron Bry.
2020 and 2021 were defining years for the burgeoning psychedelics industry. In 2021 alone, more than $730 million were invested into various psychedelic companies, both private and public.